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Background. Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to 
treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV 
for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients 
with or without compensated cirrhosis.
Methods. TURQUOISE-I, Part 2 is a phase 3 multicenter study. Patients with or without cirrhosis were HCV treatment-naive 
or -experienced, on an HIV-1 antiretroviral regimen containing atazanavir, raltegravir, dolutegravir, or darunavir (for genotype 4 only), 
and had plasma HIV-1 ribonucleic acid <40 copies/mL at screening. Patients received OBV/PTV/r ± DSV ±RBV for 12 or 24 weeks.
Results. In total, 228 patients were treated according to guidelines. Sustained virologic response at posttreatment week 12 
(SVR12) was achieved by 194 of 200 (97%) and 27 of 28 (96%) patients with HCV genotype 1 and genotype 4 infection, respectively. 
There were 2 virologic failures: 1 breakthrough and 1 relapse in a cirrhotic and a noncirrhotic patient with genotype 1b and 1a 
infection, respectively. One reinfection occurred at posttreatment week 12 in a genotype 1a-infected patient. Excluding nonvirologic 
failures, the SVR12 rates were 98% (genotype 1) and 100% (genotype 4). Adverse events were mostly mild in severity and did not 
lead to discontinuation. Laboratory abnormalities were rare.
Conclusions. The OBV/PTV/r ±DSV was well tolerated and yielded high SVR12 rates in patients with HCV genotype 1 or gen-
otype 4/HIV-1 coinfection. The OBV/PTV/r ± DSV ±RBV is a potent HCV treatment option for patients with HIV-1 coinfection, 
regardless of treatment experience.
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Worldwide, more than 2.2 million people with hepatitis C 
virus (HCV) infection are estimated to be coinfected with 
human immunodeficiency virus (HIV)-1 [1]. Coinfected 
patients remain at a greater risk for HCV disease progression 
than patients with HCV monoinfection, with an accelerated 
progression of liver disease leading to cirrhosis and hepatic 
decompensation; the risk of progression is even greater in coin-
fected patients with low CD4 T lymphocyte (CD4) cell counts 
[2–4]. In patients infected with HIV, coinfection with HCV 
is a leading cause of morbidity and mortality. Studies suggest 
that although antiretroviral therapy (ART) can reduce the rate 
of hepatic decompensation in coinfected patients, this rate is 
still higher than that observed in HCV-monoinfected patients 
[5, 6]. Therefore, effective HCV treatment in HIV-1-coinfected 
patients remains a priority.
Until recently, treatment options for coinfected patients still 
included pegylated interferon (pegIFN) with ribavirin (RBV), 
which resulted in lower overall efficacy compared with the 
same treatment in monoinfected patients. The emergence of 
direct-acting antiviral (DAA) agents has vastly improved the 
treatment landscape for HCV; most approved regimens report 
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similarly high efficacy rates, regardless of HIV-1 coinfection 
status [7–11]. The DAAs ombitasvir ([OBV] a NS5A inhibitor) 
and paritaprevir ([PTV] an NS3/4A protease inhibitor identi-
fied by AbbVie and Enanta and codosed with the pharmacoki-
netic enhancer ritonavir [r]) are approved for the treatment 
of genotype 4 infection; OBV/PTV/r with the DAA dasabuvir 
([DSV] a NS5B nonnucleoside polymerase inhibitor) with or 
without RBV is approved for treatment of genotype 1 infection 
[12, 13].
In the phase 2 trial TURQUOISE-I Part 1a, patients with 
HIV-1/HCV genotype 1 coinfection with or without cirrhosis 
achieved rates of sustained virologic response (HCV ribonu-
cleic acid [RNA]  <  lower limit of quantification [LLOQ]) at 
12 weeks posttreatment (SVR12) of 94% and 91% after OBV/
PTV/r plus DSV treatment for 12 or 24 weeks, respectively [14]. 
Based on these results, OBV/PTV/r plus DSV was approved 
for HCV genotype 1/HIV-1 coinfection and recommended in 
national and international guidelines [7, 8].
TURQUOISE-I, Part 2 is a phase 3 global trial assessing the 
efficacy and safety of OBV/PTV/r with or without DSV and 
with or without RBV in an expanded study population of 233 
patients with HIV-1/HCV genotype 1 or genotype 4 coinfection 
with or without cirrhosis.
METHODS
Study Design
TURQUOISE-I was a multipart, phase 2 and 3, partially rand-
omized, open-label study. Part 2 was a phase 3 study conducted 
at 64 sites in the United States, Canada, France, Germany, 
Italy, New Zealand, Puerto Rico, Russia, Spain, and the United 
Kingdom. Figure  1 shows the trial profile for Part 2.  Studies 
were designed according to Good Clinical Practice guide-
lines, Declaration of Helsinki, and applicable regulations, with 
independent ethics committee or institutional review board 
approval at all study sites.
Patients
Patients at least 18 years of age with chronic HCV genotype 1 
or genotype 4 infection with HCV RNA >1000 IU/mL at time 
of screening were enrolled. Eligible patients were HCV/HIV-1 
coinfected, with HIV-1 RNA <40 copies/mL (Abbott RealTime 
HIV-1 Assay) and on a stable, qualifying HIV-1 ART regimen for 
at least 8 weeks before screening. Qualified regimens included 
at least 1 nucleoside/nucleotide reverse-transcriptase inhibitor 
containing tenofovir disoproxil fumarate, emtricitabine, lami-
vudine, or abacavir, in combination with 1 or more of the fol-
lowing anchor antiretrovirals: atazanavir coadministered with 
ritonavir, raltegravir, and/or dolutegravir. Once-daily darunavir 
coadministered with ritonavir was also allowed for HCV gen-
otype 4-infected patients only, due to a drug-drug interaction 
(DDI) between DSV and darunavir. However, in a parallel study 
(TURQUOISE-I, Part 1b), the decrease in the darunavir trough 
in HCV genotype 1/HIV-1-coinfected patients was not as pro-
nounced as in healthy volunteers [15, 16]. Patients on ritona-
vir-boosted ART stopped the ritonavir component of their ART 
regimen during the treatment period and took OBV/PTV/r ± 
DSV (with or without RBV) concurrently with ART. Details 
on the dosing of qualified regimens are in the Supplementary 
Appendix.
Patients with cirrhosis were required to have Child Pugh 
A  (score  ≤6) at screening. Cirrhosis status at baseline was 
defined by liver biopsy (METAVIR score >3 or Ishak score >4), 
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Figure 1. Study design broken down by treatment arm is shown. *Arm G was omitted from this analysis because the recommended regimen for HCV genotype1b patients is 
ombitasvir, paritaprevir/ritonavir (OBV/PTV/r) plus dasabuvir (DSV) without ribavirin (RBV). GT, genotype; R, randomized treatment arms; SVR12, sustained virologic response 
at posttreatment week 12. 
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markers (FibroTest score ≥0.73 and an aspartate aminotrans-
ferase-to-platelet ratio index  >2). Patients could be (1) HCV 
treatment-naive or (2) treatment-experienced with pegIFN/
RBV or sofosbuvir plus RBV with or without pegIFN.
Exclusion criteria included presence of hepatocellular car-
cinoma, a positive test result for hepatitis B surface antigen, 
or infection with any HCV genotype other than genotype 1 
or 4. Patients could not have been previously treated with any 
DAAs other than sofosbuvir. Medications contraindicated 
for use with OBV/PTV/r ± DSV are listed in Supplementary 
Table 1. All patients provided signed informed consent before 
enrollment.
Procedures and Outcomes
Patients with HCV genotype 1 or 4 and HIV-1 coinfection, 
with or without cirrhosis, and either HCV treatment-naive or 
HCV treatment-experienced, received all-oral OBV/PTV/r 
(25/150/100 mg once-daily) with (genotype 1) or without (gen-
otype 4)  DSV (250  mg twice-daily) with or without RBV for 
12 or 24 weeks. Shortly after enrollment began, data from the 
TURQUOISE-III study became available, which demonstrated 
that 100% of patients with HCV genotype 1b and cirrhosis 
achieved SVR12 after treatment with OBV/PTV/r + DSV with-
out RBV; these data would later inform the treatment guidelines 
in this population [17]. Based on these data, enrollment of cir-
rhotic, genotype 1b patients into the randomized OBV/PTV/r 
+ DSV +RBV treatment arm was stopped, which accounts for 
the low number of patients (N = 5) enrolled in this arm. To align 
with current treatment guidelines, we present data from those 
patients with HCV genotype 1b infection who received RBV-
free treatment. For patients with HCV genotype 1a or 4 infec-
tion, RBV dosing was weight-based at 1000 or 1200 mg divided 
twice daily, with the exception of patients with creatinine clear-
ance <50 mL/min who received renally adjusted doses of RBV 
as per label guidelines [18].
The primary endpoint for Part 2 of this study was the pro-
portion of patients achieving SVR12; plasma HCV RNA lev-
els were quantified using the Roche COBAS TaqMan real-time 
reverse-transcriptase polymerase chain reaction assay, version 
2.0. The LLOQ for this assay is 25 IU/mL. Unless otherwise 
indicated, analyses were conducted in the intention-to-treat 
population (ITT), which includes all patients who received at 
least 1 dose of study drug.
The proportion of patients with on-treatment HCV viro-
logic failure, posttreatment relapse, and maintenance of HIV-1 
suppression were secondary endpoints. Plasma HIV-1 RNA 
was quantified using Abbott RealTime HIV-1 Assay. Failure to 
maintain HIV-1 suppression was defined as (1) plasma HIV-1 
RNA ≥40 copies/mL followed by a repeat HIV-1 RNA of ≥200 
copies/mL or (2) 3 consecutive plasma HIV-1 RNA values ≥40 
copies/mL.
Analysis of HCV resistance was performed for patients who 
did not achieve SVR12. Pre-existing amino acid polymorphisms 
and treatment-emergent amino acid substitutions in HCV 
NS3, NS5A, and NS5B were identified by population sequenc-
ing (detection threshold ~15%). Safety and tolerability were 
assessed by monitoring of adverse events and conduction of 
physical examination and clinical laboratory and hematology 
tests at screening and throughout the study period.
Statistical Analyses
The primary efficacy endpoint was the proportion of genotype 
1-infected patients on a label-recommended regimen achieving 
SVR12 compared to the SVR12 rate achieved with the stand-
ard of care at the time of study design (sofosbuvir plus RBV) 
for HCV/HIV-1-coinfected patients [10]. Noninferiority to the 
historical control used a prespecified 10.5% margin and was 
achieved if the lower confidence bound of the 2-sided 95% con-
fidence interval (LCB) for the percentage of patients achieving 
SVR12 exceeded 74% (ie, 84%−10.5%). The noninferiority anal-
ysis was conducted in the genotype 1 analysis group, defined as 
all sofosbuvir-naive, genotype 1-infected patients treated per 
dosing recommendations (all sofosbuvir-experienced patients 
were excluded from this analysis, as were the 5 cirrhotic, geno-
type 1b-infected patients who took OBV/PTV/r + DSV + RBV 
for 12 weeks) [12]. For the primary efficacy endpoint, a sample 
size of approximately 180 genotype 1-infected patients was cal-
culated assuming an SVR12 rate of 85% to provide 95% power 
to demonstrate noninferiority compared with the historical 
control rate with a 2-sided 95% LCB greater than 74% using the 
normal approximation to the binomial proportion in a 1-sam-
ple test. For all efficacy analyses, the confidence intervals (CIs) 
were 2-sided with a significance level of 0.05 using the Wilson 
score method for the binomial proportion. The primary analy-
sis was conducted on the ITT population. A sensitivity analysis 
was performed on the modified ITT-genotype-virologic fail-
ure (mITT-GT-VF) populations. This population excluded (1) 
patients who did not have HCV genotype 1 or genotype 4 infec-
tion to prevent any bias occurring from the enrolled population 
deviating from the population intended to be studied as well 
as (2) patients who did not achieve SVR12 due to nonvirologic 
reasons to exclude those failures unrelated to the efficacy of the 
study drug. Monitoring of adverse events and laboratory abnor-
malities was performed on all patients who received at least 1 
dose of study drug. All statistical analyses were performed using 
SAS software, version 9.3 (SAS Institute).
RESULTS
Patients were recruited between July 7, 2015 and November 
2, 2015. A total of 332 patients were screened; the primary 
reason for screen failure was unmet eligibility criteria. Of the 
233 patients enrolled and treated, 5 genotype1b-infected, cir-
rhotic patients who received OBV/PTV/r + DSV + RBV for 12 
weeks were excluded from the analyses to align with current 
label recommendations and European guidelines [7, 12]; 4 of 
these patients went on to achieve SVR12. Of the remaining 228 
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patients, 200 had genotype 1 infection and 28 had genotype 4 
infection (Figure 1). Patients with genotype 1 infection were 
mostly genotype 1a (153 of 200; 77%), HCV treatment naive (134 
of 200; 67%), and noncirrhotic (177 of 200; 89%). The median 
baseline CD4+ T-cell count was 612 cells/mm3 in patients with 
genotype 1 infection, and 731 cells/mm3 in patients with geno-
type 4 infection. Of the HIV-1 anchor antiretrovirals allowed in 
this study, raltegravir was the most common (50%) in patients 
with genotype 1 infection, and dolutegravir was most common 
(39%) in patients with genotype 4 infection. Complete demo-
graphics are shown in Table 1.
SVR12 was achieved by 194 of 200 (97%; 95% CI, 93.6–
98.6) patients with genotype 1 infection, demonstrating non-
inferiority to the historical control. In the 28 patients with 
genotype 4 infection, 27 (96%; 95% CI, 82.3–99.4) achieved 
SVR12 (Figure 2). Two virologic failures occurred. One geno-
type 1b-infected patient with cirrhosis, a non-CC (TT) IL28B 
genotype, and a prior null response to pegIFN/RBV had 
on-treatment virologic breakthrough at treatment week 10; 
this patient was 100% treatment compliant, and drug concen-
trations from sparse pharmacokinetic samples were consistent 
with the patient being adherent. One genotype 1a-infected, 
treatment-naive patient without cirrhosis treated for 12 weeks 
experienced relapse at post-treatment week 4. In addition, 1 
genotype1a-infected patient had a reinfection at post-treatment 
week 12, as determined by phylogenetic analysis (Supplemental 
Figure 2). The mITT-GT-VF analysis excluded 1 genotype 
4-infected patient who prematurely discontinued treatment 
and 4 genotype1-infected patients: 2 prematurely discontinued 
treatment, 1 was lost to follow up, and 1 with undeterminable 
genotype who enrolled in the genotype 1 treatment group who 
did go on to achieve SVR12. All 3 patients who prematurely 
discontinued treatment had HCV RNA below LLOQ at time 
of discontinuation. Excluding these patients, SVR12 rates were 
98% (193 of 196) and 100% (27 of 27) in patients with genotype 
1 and genotype 4 infections, respectively.
The SVR12 rates were not notably impacted by HCV sub-
type, ART regimen, cirrhosis status, or prior treatment expe-
rience (Supplemental Figure  3). Although a small number of 
patients with prior sofosbuvir experience were enrolled, all 
achieved SVR12.
Population sequencing of the regions encoding HCV NS3, 
NS5A, and NS5B was conducted on samples taken at baseline 
and the time of failure from patients who experienced viro-
logic failure. The genotype 1b-infected patient with on-treat-
ment virologic failure had no baseline polymorphisms in NS3 
or NS5A, but C316N and S556G were present in NS5B; at the 
Table 1. Baseline Demographics
Characteristica




Male, n (%) 156 (78) 26 (93)
White race, n (%)b 173 (87) 25 (89)
Black race, n (%)b 19 (10) 3 (11)
Hispanic or Latino ethnicity, n (%)b 26 (13) 1 (4)
Age, median (range), years 50 (26–69) 47 (30–63)
BMI, median (range), kg/m2 25 (17–41) 24 (15–38)
HCV genotype 1a, n (%)c 153 (77) –
IL28B non-CC genotype 133 (67) 21 (75)
Prior HCV Treatment History
 Treatment naive 134 (67) 17 (61)
 PegIFN/RBV 62 (31) 11 (39)
 SOF-RBV 3 (2) 0
HCV RNA, median (range), log10 IU/mL 6.5 (1.8–7.6) 6.0 (4.7–7.0)
CD4+ cell count, median (range), /µL 612 (133–2351) 731 (262–1533)
HIV-1 RNA <40 copies/mL, n (%) 193 (97) 27 (96)
Baseline Fibrosis Staged
 F0-1 139 (70) 21 (75)
 F2 20 (10) 2 (7)
 F3 17 (9) 5 (18)
 F4 23 (12) 0
ART Regimen
 Darunavir/r – 8 (29)
 Atazanavir/r 44 (22) 2 (7)
 Raltegravir 100 (50) 7 (25)
 Dolutegravir 56 (28) 11 (39)
History of injection drug use 105 (54) 4 (15)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; 
HIV, human immunodeficiency virus; PegIFN, pegylated interferon; r, ritonavir; RBV, ribavi-
rin; RNA, ribonucleic acid; SOF, sofosbuvir.
aPercentage totals exceeding 100% due to rounding.
bRace and ethnicity were self-reported. 
cGenotypes were determined by the Versant HCV Genotype Inno-LiPA Assay, version 2.0, 
or Sanger sequencing assay.


























































Figure 2. The number and percentage of patients with genotype 1 ([GT1] blue) 
and GT4 (teal) infection who achieved sustained virologic response at posttreat-
ment week 12 (SVR12) are shown in the intention-to-treat population (ITT) (solid) 
and modified ITT ([mITT] cross-hatched) populations. *Patient with reinfection is 
included in the mITT analysis for not achieving SVR12, and not excluded from the 
denominator as a non-virologic failure. One patient included in the ITT analysis 
(N = 200) who achieved SVR12 was excluded from the mITT analysis due to having 
undetermined genotype, bringing N = 99 (minus 3 non-virologic failures, N = 196). 
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time of failure, Y56H and D168V in NS3, Y93H in NS5A, and 
C316N and S556G in NS5B were present. There were no base-
line polymorphisms or treatment-emergent substitutions found 
in NS3, NS5A, or NS5B in the genotype1a-infected patient that 
experienced relapse.
Adverse events were mostly mild in severity (Table 2). There 
were no discontinuations due to adverse events. Serious adverse 
events occurred in 9 (4.5%) and 1 (4%) of patients with genotype 
1 and 4 infection, respectively (Supplementary Table  2). One 
genotype 1a-infected patient in the 24-week treatment arm with 
a previous history of depression experienced serious adverse 
events of anemia on week 4 and depression on week 17 that 
were assessed by the treating physician as having a reasonable 
possibility of being related to RBV and DAAs, respectively. The 
patient’s RBV dose was adjusted, and the anemia resolved after 
5 days. Grade 3 or higher total bilirubin elevations occurred in 
27 of 200 (14%) and 2 of 28 (7%) genotype 1 and 4 patients, 
respectively, and were predominantly indirect; 25 of these 
patients were on an ART regimen that contained atazanavir. 
The Grade 3 bilirubin elevations that occurred in the remain-
ing 4 patients were due to RBV-induced hemolysis and, to a 
lesser degree, paritaprevir inhibition of transporters/enzymes 
involved with bilirubin metabolism. Of the 182 patients on a 
RBV-containing regimen, 12% experienced a decline in hemo-
globin that resulted in a RBV dose modification.
Ten (4%) patients experienced episodes of intermittent HIV 
viremia (≥40 copies/mL) while taking study drug. The HIV-1 
RNA values among these 10 patients never exceeded 200 cop-
ies/mL and thus did not meet the criteria for HIV-1 genotypic 
resistance testing. No patients met prespecified failure to main-
tain HIV-1 RNA suppression, and no patients required a change 
to ART while on HCV treatment.
DISCUSSION
The advent of DAA regimens for HCV treatment has resulted in 
improved outcomes for patients with HCV/HIV-1 coinfection; 
many approved therapies recommend the same regimen for 
coinfected patients as for HCV-monoinfected patients, and the 
majority of restrictions are regarding baseline HCV RNA and 
possible DDIs with specific ART [7, 8]. In TURQUOISE-I Part 
2, we investigated OBV/PTV/r with or without DSV and with 
or without RBV in a large cohort of patients with HIV-1 coin-
fection on atazanavir coadministered with ritonavir, raltegravir, 
dolutegravir, or for genotype 4-infected patients only, darun-
avir coadministered with ritonavir. In addition to expanding 
the patient population to include HCV genotype 4-coinfected 
patients, Part 2 of the study also expanded the allowed ART reg-
imens to include darunavir for patients with genotype 4 infec-
tion and dolutegravir for all patients, in addition to the anchor 
agents atazanavir and raltegravir that were allowed in Part I of 
the study [14]. Treatment was based on the label recommen-
dations for patients with HCV genotype 1a, 1b or 4 infection, 
regardless of HIV-1 status.
Treatment with OBV/PTV/r + DSV ± RBV for genotype 
1 and OBV/PTV/r + RBV for genotype 4-coinfected patients 
yielded SVR12 rates of 97% and 96%, respectively. There were 
no virologic failures in patients with genotype 4 HCV/HIV 
coinfection. In the genotype 1a-infected patient with relapse, 
there were no baseline polymorphisms or treatment-emergent 
substitutions found in NS3, NS5A, or NS5B. The genotype 
1b-infected patient with on-treatment virologic failure had 
C316N and S556G in NS5B both at baseline and at the time of 
failure; no baseline polymorphisms were present in either NS3 
or NS5A, but Y56H and D168 in NS3 and Y93H in NS5A were 
present at time of failure. In the patient who relapsed, the lack of 
baseline polymorphisms or treatment-emergent substitutions 
is interesting; a pooled resistance analysis of 74 patients with 
virologic failure in phase 2 and 3 clinical trials investigating 
OBV/PTV/r +DSV ±RBV revealed that although the majority 
of patients had treatment-emergent substitutions in at least 1 
target, 15% had no treatment-emergent substitutions in any tar-
get [19].
The direct-acting antivirals were well tolerated, with no 
discontinuations due to adverse events. Grade 3 bilirubin 
elevations were primarily indirect and occurred mostly in 
patients on either or both an atazanavir-containing ART 
and RBV-containing regimen; the elevations did not lead to 






Any AE 169 (85) 24 (86)
AEs leading to study drug discontinuation 0 0
Serious AE 9 (5)a 1 (4)
AEs in ≥10% of overall patients
 Fatigue 48 (24) 5 (18)
 Nausea 42 (21) 5 (18)
 Diarrhea 32 (16) 1 (4)
 Headache 28 (14) 5 (18)
 Insomnia 30 (15) 2 (7)
 Pruritus 22 (11) 1 (4)
 HGB decrease 19 (10) 4 (14)
  HGB decreases leading to RBV modification 18 (9) 3 (11)
AST Grade ≥3 (>5 × ULN)b 0 0
ALT Grade 3 (5–10 × ULN)b 1 (1) 0
ALT Grade 4 (>10 × ULN)b 0 0
Total Bilirubin Grade 3 (3–10 × ULN) 26 (13) 2 (7)
Total Bilirubin Grade 4 (>10 × ULN) 1 (0.5) 0
Patients with Grade 3–4 Bilirubin elevations 
receiving ATV-containing ART, n/N (%)
23 of 26 (88) 2 of 2 (100)
Hemoglobin Grade 2 (8–10 g/dL) 15 (8)c 0
Hemoglobin Grade 3 (<8 g/dL) 0 0
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; ATV, atazanavir; DAAs, direct-acting antiviral agents; HGB, hemoglobin; RBV, 
ribavirin; ULN, upper limit of normal.
aOne serious AE of depression on day 123 was deemed by the treating physician as hav-
ing a reasonable possibility of being related to DAAs.
bPostnadir.
cFourteen of fifteen patients with HGB reductions were on RBV-containing regimen.
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discontinuation nor were they associated with worsening 
hepatic function. All patients maintained suppression of HIV 
RNA during the treatment period.
Since the time of study design, several regimens have been 
approved and many have yielded high SVR rates in patients with 
HCV/HIV-1 coinfection. Similar to TURQUOISE-I Part 2, the 
ION-4 study was conducted in patients with HCV genotype 1 or 
4 and HIV-1 coinfection, and it included cirrhotic patients and 
those with prior HCV treatment experience. A 12-week treat-
ment duration with ledipasvir/sofosbuvir resulted in SVR12 
rates of 96% in 327 genotype 1-infected patients and 100% in 
8 genotype 4-infected patients, with 2 virologic breakthroughs 
and 10 relapses. All 10 patients who relapsed were black, and 
black race was the only significant predictor of relapse, occur-
ring in 10 of 115 (9%) black patients [20]. Although cross-study 
comparisons should be interpreted with caution, it is encourag-
ing that of the 22 black patients enrolled in TURQUOISE-I Part 
2, 1 patient experienced relapse, and this was the only relapse 
in the study; although conclusions cannot be made with sta-
tistical accuracy, this observation is confirmed by the results 
of TURQUOISE-I, Part 1b, wherein 41% (9 of 22) of patients 
were black, and all achieved SVR12 [16]. Together, these results 
support previous results indicating that black race is not a 
predictor of relapse with the OBV/PTV/r plus DSV regimen 
[21]. The recent C-EDGE CO-INFECTION study conducted 
in treatment-naive patients with HCV genotype 1, 4, or 6 and 
HIV coinfection demonstrated that 96% (210 of 218) of patients 
achieved SVR12 after 12 weeks of treatment with elbasvir/gra-
zoprevir, with 5 patients (2%) experiencing relapse [22]. Of 
interest is the observational study by Milazzo et al [23], which 
reported real-life treatment outcomes of 5 different DAA reg-
imens, including OBV/PTV/r plus DSV, in HCV-infected 
patients with or without HIV coinfection; RBV was used in 38% 
of patients regardless of regimen and in accordance with EASL 
guidelines. Safety was consistent across all regimens, and effi-
cacy comparable with that observed in clinical trials. This is par-
ticularly relevant because although several DAA regimens have 
been approved since the time of this study’s design that offer 
shorter treatment durations or RBV-free treatment options, the 
availability of these regimens varies widely, particularly in areas 
with limited resources.
CONCLUSIONS
Limitations of this study include the small number of patients 
enrolled in certain subgroups, specifically those with cirrhosis, 
black race, and prior sofosbuvir experience, and that no geno-
type 4-infected patients with cirrhosis enrolled. One additional 
limitation was that nonnucleoside reverse-transcriptase inhibi-
tors were not allowed in the ART regimens.
Human immunodeficiency virus-1 patients on certain 
stable ART regimens coinfected with HCV genotype 1 or 4 
can be successfully treated with OBV/PTV/r with or without 
DSV, respectively. Treatment with OBV/PTV/r with or with-
out DSV, either with or without RBV, demonstrated favorable 
efficacy and tolerability in important subpopulations, includ-
ing those with prior treatment experience and cirrhosis.
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